Journal of Clinical Endocrinology & Metabolism, Vol 77, 1246-1250, Copyright © 1993 by Endocrine Society

ARTICLES

Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid

J Shemer, A Yaron, H Werner, ZM Shao, MS Sheikh, JA Fontana, D LeRoith and CT Roberts Jr
Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.

The T47D human breast carcinoma cell line has been shown to synthesize insulin-like growth factor-I (IGF-I) binding proteins (IGFBPs) and IGF- I receptors, and to exhibit a mitogenic response to exogenous IGF-I. We have used T47D cells to investigate the regulation of IGFBPs by IGF-I and retinoic acid (RA), agents that affect cell proliferation and have been shown to regulate IGFBP levels in other cell types. Exposure of T47D cells to IGF-I resulted in the appearance of IGFBP-2, -4, and -5 in conditioned medium but had no effect on the levels of IGFBPs in Triton X-100-extracted cells. This effect was most pronounced for IGFBP- 5 and was also elicited by an IGF-I analog that retains affinity for IGFBPs but not by insulin or IGF analogs that have decreased affinity for IGFBPs. Additionally, this effect was not associated with a change in IGFBP-5 messenger RNA (mRNA) levels; however, the appearance of IGFBP-5 in the conditioned medium was inhibited by an anti-IGF-I receptor antibody (alpha IR-3). RA decreased IGFBP-5 mRNA levels and cell-associated IGFBP-5 in both the presence and absence of IGF-I and inhibited the IGF-I-stimulated secretion of IGFBP-5 into T47D cell conditioned medium. These results suggest that IGF-I increases IGFBP-5 levels in the T47D cell line both through direct interaction with IGFBP- 5 as well as through a receptor-mediated process that does not require direct interaction with IGFBPs. The latter results are consistent with an effect of IGF-I on a factor that may modulate an IGFBP protease activity. The inhibitory effect of RA, on the other hand, appears to be due primarily to regulation of IGFBP-5 mRNA levels. Thus, IGFBP-5 accumulation appears to be positively regulated by IGF-I, potentially at the level of susceptibility to proteolysis, and negatively regulated at the level of gene expression by RA.

This article has been cited by other articles:

				M. A Meester-Smoor, A. C Molijn, Y. Zhao, N. A Groen, C. A H Groffen, M. Boogaard, D. van Dalsum-Verbiest, G. C Grosveld, and E. C Zwarthoff The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence J. Mol. Endocrinol., January 1, 2007; 38(1): 113 - 125. [Abstract] [Full Text] [PDF]

				A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W. F. Blum, H. J. Kolb, M. M. Weber, and E. Wolf Insulin-like Growth Factor-binding Protein 2 in Tumorigenesis: Protector or Promoter? Cancer Res., December 1, 2001; 61(24): 8601 - 8610. [Full Text] [PDF]

				I. M. Holdaway, A. E. Lethaby, B. H. Mason, V. Singh, J. E. Harman, M. MacCormick, and I. D. Civil Effect of Breast Surgery on Serum Levels of Insulin-Like Growth Factors (IGF-I, IGF-II, and IGF Binding Protein-3) in Women With Benign and Malignant Breast Lesions Ann. Surg. Oncol., January 1, 2001; 8(1): 25 - 31. [Abstract] [Full Text] [PDF]

				L. J. Schedlich, T. F. Young, S. M. Firth, and R. C. Baxter Insulin-like Growth Factor-binding Protein (IGFBP)-3 and IGFBP-5 Share a Common Nuclear Transport Pathway in T47D Human Breast Carcinoma Cells J. Biol. Chem., July 17, 1998; 273(29): 18347 - 18352. [Abstract] [Full Text] [PDF]

				C. Duan, S. B. Hawes, T. Prevette, and D. R. Clemmons Insulin-like Growth Factor-I (IGF-I) Regulates IGF-binding Protein-5 Synthesis through Transcriptional Activation of the Gene in Aortic Smooth Muscle Cells J. Biol. Chem., February 23, 1996; 271(8): 4280 - 4288. [Abstract] [Full Text] [PDF]

				C. Duan and D. R. Clemmons Transcription Factor AP-2 Regulates Human Insulin-like Growth Factor Binding Protein-5 Gene Expression J. Biol. Chem., October 20, 1995; 270(42): 24844 - 24851. [Abstract] [Full Text] [PDF]